Benefits
Skin moisture and elasticity
A 2021 pooled analysis of nine oral randomized trials found astaxanthin improved skin moisture and elasticity versus placebo, but did not significantly reduce wrinkle depth. In a 16-week maker-funded AstaReal trial in 65 women, wrinkle and moisture measures worsened on placebo during autumn but held steady at 6 or 12 mg a day.
Lower oxidative stress markers
A pooled analysis of 12 placebo-controlled trials with 380 people found astaxanthin lowered blood malondialdehyde, a marker of oxidative damage to fats. Few trials measured other markers. Blood CRP and TNF-alpha did not change significantly. These are laboratory measures, not proven health outcomes, and the analysis covered astaxanthin in general, not AstaReal specifically.
Eye comfort during screen use
In a randomized placebo-controlled trial in 64 children aged 10 to 14 with at least 4 hours of daily screen time, AstaReal astaxanthin at 4 mg a day for 84 days improved eye-strain questionnaire scores about 20% more than placebo. Visual acuity and near focusing distance did not change. The trial was run by the maker.
Mechanism of action
Antioxidant activity in cell membranes
Astaxanthin's long molecule can sit across cell membranes, where in laboratory studies it quenches singlet oxygen and free radicals. In people, the main measured effect is lower blood malondialdehyde, a marker of oxidative damage to fats.
Inflammatory signaling
In skin cells exposed to UVB light in the lab, astaxanthin reduced inflammatory cytokine release and the collagen-degrading enzyme MMP-1. In people, a meta-analysis found lower IL-6 only in trials of adults with type 2 diabetes, and no significant change in CRP or TNF-alpha.
Clinical trials
Systematic review and meta-analysis of nine randomized controlled trials of oral astaxanthin and two open-label studies of topical or combined use. (Zhou et al. 2021, Nutrients)
Adults in nine oral randomized trials of astaxanthin; the analysis was not specific to AstaReal.
Oral astaxanthin improved skin moisture (SMD 0.53) and elasticity (SMD 0.77) versus placebo, but did not significantly reduce wrinkle depth (SMD -0.26, p=0.11).
Randomized, double-blind, placebo-controlled trial: AstaReal astaxanthin 4 mg a day or placebo for 84 days. Several authors were employed by Fuji Chemical or AstaReal companies. (Hecht et al. 2025, Adv Ther)
64 children aged 10 to 14 with at least 4 hours of daily screen time and mild to moderate eye-strain symptoms.
Eye-strain questionnaire scores improved more than with placebo, a 20% between-group difference, and visual fatigue scores were lower. There was no significant difference in visual acuity, near point of accommodation, tear test results or immune markers.
Randomized, double-blind, placebo-controlled trial: AstaReal astaxanthin 6 mg or 12 mg a day, or placebo, for 16 weeks from August to December. Sponsored by Fuji Chemical Industries. (Tominaga et al. 2017, J Clin Biochem Nutr)
65 healthy women in Japan.
Wrinkle measures and skin moisture worsened significantly in the placebo group, while no significant change occurred in the astaxanthin groups. A skin inflammation marker (IL-1 alpha) rose in the placebo and 6 mg groups but not at 12 mg. The result shows less decline rather than improvement.